Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc. develops clinical-stage biotechnology programs for hematologic diseases, led by burixafor (GPC-100), a highly selective small-molecule CXCR4 antagonist. Company updates center on burixafor's role in hematopoietic stem cell mobilization for multiple myeloma transplant settings, sickle cell disease, cell and gene therapy support, and acute myeloid leukemia chemosensitization.
Recurring news also covers clinical data presentations and publications, collaborations for combination approaches, financial results, liquidity disclosures, and research spending following Exicure's acquisition of GPCR Therapeutics USA. Earlier company context includes its historical focus on nucleic acid therapies and restructuring before the current hematology-focused pipeline.
Exicure (Nasdaq:XCUR) announced Board and committee changes effective June 30, 2026, following a June 24 special meeting.
Jung Kyu Ham resigned as director. Jin Young Go and Eui Seok Han were appointed Class III directors, expanding the Board from five to six members. The Board affirmed Nasdaq independence compliance and updated Audit and Compensation Committee memberships.
Exicure (Nasdaq:XCUR) received a Nasdaq notice on June 5, 2026 for not meeting the $2.5 million minimum stockholders’ equity requirement under Rule 5550(b)(1). Reported equity was about $2.1 million as of March 31, 2026, and alternative listing standards are also not satisfied.
The notice does not immediately affect listing. Exicure has until July 20, 2026 to submit a compliance plan and may receive up to 180 days from the notice date to regain compliance. The company is evaluating options and continues to pursue its hematologic disease program.
Exicure (Nasdaq:XCUR) received a Nasdaq Listing Qualifications notice on May 28, 2026 for non-compliance with Rule 5250(c)(1) due to a delayed Form 10-Q for Q1 2026. The delay stemmed from changes in financial reporting personnel and procedures. Exicure filed the Form 10-Q on May 29, 2026 and believes it has regained compliance.
Exicure (Nasdaq: XCUR) announced a co-development agreement with Adbiotech (KOSDAQ: 179530) on April 22, 2026, to explore combination therapies using Burixafor (GPC-100) across sickle cell disease, AML, and solid tumors.
Under the deal, Adbiotech will run in vivo and preclinical validation while Exicure supplies Burixafor and leads clinical and regulatory strategy. Burixafor completed a Phase 2 trial in multiple myeloma last year. Parties may advance selected programs to IND-enabling studies and clinical trials, subject to further agreements and funding; budget, IP, and commercialization terms remain to be finalized.
Exicure (Nasdaq: XCUR) reported full-year 2025 results. Cash and cash equivalents were $3.7 million at December 31, 2025, down from $12.5 million a year earlier, and management states current liquidity may be insufficient to fund operations for the next 12 months.
Net loss narrowed to $4.9 million in 2025 from $9.7 million in 2024, driven largely by a $6.0 million gain from early lease termination; R&D and G&A expenses rose after the acquisition of GPCR Therapeutics USA.
Exicure (Nasdaq: XCUR) announced publication in Annals of Hematology reporting Phase 2 data for burixafor (GPC-100/TG-0054), a selective CXCR4 inhibitor. In a 12-participant study, 11 of 12 (92%) collected ≥5.0×10⁶ CD34+ cells/kg within two sessions; six achieved this in one session. Median neutrophil and platelet engraftment were 12 and 22 days. Peak CD34+ mobilization occurred within one hour, enabling same-day leukapheresis and marked lymphocyte increases (up to 11-fold in MM patients). Burixafor was generally well tolerated with two low-grade treatment-related adverse events. Exicure is advancing further Phase 2 studies including a propranolol combination.
Exicure (Nasdaq: XCUR) will present a poster at the 2026 Tandem Meetings (ASTCT/CIBMTR) in Salt Lake City on February 5, 2026, summarizing results from its open-label, multicenter Phase 2 trial (NCT05561751) of burixafor for hematopoietic progenitor cell mobilization in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.
The company reported positive topline data showing 89.7% of patients met the trial primary endpoint; burixafor was given with propranolol and G-CSF and enabled same-day administration and leukapheresis with a reported favorable safety profile.
Exicure (Nasdaq: XCUR) reported positive topline Phase 2 results for burixafor (GPC-100) combined with propranolol and G-CSF for hematopoietic progenitor cell mobilization in multiple myeloma.
In the open-label, multicenter trial (NCT05561751), 17 of 19 participants (89.5%) collected ≥2×10⁶ CD34+ cells/kg within two leukapheresis sessions; two required an additional session. Median time to neutrophil engraftment was 13 days and platelet engraftment 17.5 days. Peak peripheral CD34+ levels occurred within one hour after dosing. Among 16 participants with prior daratumumab, 14 (87.5%) met the primary endpoint. Burixafor with propranolol and G-CSF was well tolerated with no burixafor-related adverse events >Grade 2.
Exicure (Nasdaq: XCUR) reported third quarter 2025 results for the quarter ended September 30, 2025.
Key figures: cash and cash equivalents $4.4M (Sept 30, 2025 vs $12.5M on Dec 31, 2024), R&D $0.9M, G&A $1.5M, and net loss $2.4M for Q3 2025. The company recorded a $246K loss from a contingent liability change and a $155K gain related to a self-insured retainer settlement.
Management stated cash is not sufficient to fund operations and said substantial additional financing is needed in the short term.
Exicure (Nasdaq: XCUR) announced that completed Phase 2 data for burixafor, a CXCR4 antagonist, will be presented orally at the 67th ASH Annual Meeting on December 8, 2025. The oral presentation (Abstract 1050) reports results from an open-label, multicenter Phase 2 trial (NCT05561751) of burixafor plus G-CSF and propranolol to mobilize hematopoietic progenitor cells in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.
The presentation highlights an excellent safety profile, same-day administration with leukapheresis, and that 18 of 19 patients who chose transplant proceeded to AHCT; many enrolled patients had prior daratumumab exposure. Presenter: Dr. Jack Khouri. Session: Cell Collection and Manufacturing; 5:45–6:00pm EST, Hyatt Regency Ballroom R.